TRAF6 and colorectal carcinoma: Overall, the study delineates a novel antimetastatic mechanism in which RSV inhibits CRC progression through the activation of the miR-125b-5p/TRAF6 axis, highlighting its therapeutic potential, especially in patients with diminished miR-125b-5p expression (44).